AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
3 reports, 2 independent
Updated Nov 1
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.AstraZeneca submitted NDA to FDA and MAA to EMA following ESMO data presentation.1 source
Trial results for AstraZeneca's IMFINZI cancer therapy were presented at the ESMO Congress in Madrid.1 source
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
European Society for Medical Oncology
Professional organisation
Nothing else this week.